Prior studies have revealed a strong correlation of CASC9 with hepatocellular carcinoma, breast cancer, osteosarcoma, and pancreatic cancer progression [26–29] and its role in enhancing tumor resistance to gefitinib and gemcitabine [30–32]. Here, CASC9 is linked to breast carcinoma.